MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.

In a decision signed Monday, North Carolina federal judge Kenneth Bell granted Merck’s motion to dismiss the claims of ...

Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company executive said on Wednesday."By the end ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck opens new, $1 billion, 225,000-sq ft facility dedicated to vaccine manufacturing at its Durham, North Carolina, site: Durham, North Carolina Wednesday, March 12, 2025, 09:00 ...

MSD’s HIV treatment is now back on track after ... which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck & Co. (MSD outside the U.S. and Canada) has just unveiled a brand-new, cutting-edge vaccine manufacturing facility at ...

This expansion of our Durham plant is a crucial component of the more than $12 billion Merck has invested toward U.S. capital ...